Type 1 Diabetes

At ATTD 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, have an extended conversation with the new chief operating officer at Dexcom, Jake Leach, to discuss the global and US rollouts of the Dexcom G7 and what the future might hold for Dexcom.

A pilot study presented at ATTD 23 is providing further insight into the potential role of inhaled insulin in type 1 diabetes.

David Maahs, MD, PhD, sits down to discuss data he presented at ATTD 2023 and provide perspective on ongoing issues plaguing the diabetes community, including optimization of telehealth and addressing disparities in care.

An analysis of Veterans Affairs data from more than 20,000 people with diabetes provides an overview of the associations of CGM initiation with improved glycemic control and reduced hospitalization in this patient population.

An analysis of data from more than 5000 youths with T1D offers insight into the comparative ability of different treatment modalities for achieving glycemic control and optimal time in range.

Teresa Quattrin, MD, reviews emerging clinical trial data on novel therapies to delay the progression of type 1 diabetes.

Kimberly Simmons, MD, MPH/MSPH, leads a discussion on long-term monitoring for patients with type 1 diabetes and which providers are most likely to administer and manage teplizumab treatment.

An analysis of NHIS data from 2016-2021 indicates the rate of overweight or obesity among adults with type 1 diabetes was comparable to the rate among the general population, but these people were less likely to receive lifestyle recommendations from their providers.

Experts in endocrinology share their approach to patient selection for teplizumab in type 1 diabetes and the impact of a 2-year delay in the onset of the disease.

Dr Kimberly Simmons reviews key findings from an initial study and extended follow-up on the safety and efficacy of teplizumab in delaying the progression of type 1 diabetes.

Robin S. Goland, MD, and Kimberly Simmons, MD, MPH/MSPH, provide insight on teplizumab, which was recently approved by the FDA, to delay the progression of type 1 diabetes, and they discuss the implications of autoantibody detection in patients.

Dr Teresa Quattrin discusses the significance of delaying the onset of type 1 diabetes.

Drs Diana Isaacs and Natalie Bellini highlight the need for engaging patients in shared decision-making and addressing social determinants of health in diabetes and obesity management in adults and pediatric patients.

Scott Kahan, MD, MPH, discusses with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, how the controversial use of new diabetes and obesity medications is creating access issues for people who really need these medications, and shares strategies to initiate the conversation about weight management with patients.

Dr Scott Kahan shares the latest updates to the 2023 ADA Standards of Care related to weight management and describes the different weight loss approaches recommended by the ADA.

Scott Kahan, MD, MPH, discusses the shortcomings of the current staging systems used for overweight and obesity and recommends the use of weight-related health and functional status in addition to BMI.

Teresa Quattrin, MD, leads a discussion on the benefits of using medications for type 2 diabetes to manage patients who have type 1 diabetes.

Kimberly Simmons, MD, MPH/MSPH, reviews ADA guidelines recommendations for the management of type 1 diabetes.

Drs Diana Isaacs and Natalie Bellini highlight the need for improved screening, greater awareness of clinical trial opportunities, and clinician education to improve early diagnosis and outcomes for people with T1D.

Sumita Singh, a T1D advocate, discusses with Diana Isaacs and Natalie Bellini how teplizumab and other advances are providing hope to the T1D community and talks about the challenges and needs of a diverse T1D patient population.

Sumita Singh, a T1D advocate, discusses her family’s decision to enroll their daughter Bella in a clinical trial for T1D and shares their experience.

Sumita Singh shares about her daughter Bella’s type 1 diabetes (T1D) diagnosis and how their family navigated the logistical and emotional challenges of receiving a T1D diagnosis.

Dr Kimberly Simmons and Dr Teresa Quattrin examine the diagnostic process and importance of screening for type 1 diabetes.

Robert Busch, MD, and Robin S. Goland, MD, review the prevalence and pathophysiology of type 1 diabetes.

Drs Diana Isaacs and Natalie Bellini discuss the everyday challenges of managing type 1 diabetes and underscore the need for new treatments to improve the quality of life for people living with type 1 diabetes

Expert healthcare practitioners discuss the potential of CGM and other technology to identify signs of type 1 diabetes.

Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.

Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.

A systematic review of nearly 100 published studies provides an overview of sex-based disparities in the care of pediatric patients with type 1 diabetes.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.